H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm 'Buy' Ratings on Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is included in our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds.

On August 8, 2025, H.C. Wainwright reaffirmed its ‘Buy’ rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) with a $16 price target. The near completion of Phase 3 recruitment for avexitide in post-bariatric hypoglycemia (PBH) boosted analyst sentiment. Previously, the Phase 2b results showed that the drug was shown to reduce hypoglycemic events significantly. Furthermore, the drug holds the potential to be priced at around $144,000 per patient annually, given its orphan drug and breakthrough therapy designations. Following the expected launch in 2027, the analyst expects sales to jump from $10 million in 2028 to $320 million by 2034.

Meanwhile, on August 7, Leerink Partners also reiterated its ‘Buy’ rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), preceded by TD Cowen’s ‘Buy’ rating on July 23.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) develops treatments for neurodegenerative and endocrine diseases. It is included in our list of the Best Single Digit Stocks.

While we acknowledge the potential of AMLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts.

Disclosure: None.